• 提示：詳情請(qǐng)下載說明書。

• 產(chǎn)品描述： Cediranib maleate (AZD-2171 maleate) is a highly potent, orally available VEGFR inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively.

• 靶點(diǎn)： Flt-1:5 nM (IC50);KDR:1 nM (IC50);Flt-4:3 nM (IC50);PDGFRα:36 nM (IC50);PDGFRβ:5 nM (IC50);c-Kit:2 nM (IC50)

• 體內(nèi)研究：
  Once-daily oral administration of Cediranib ablates experimental (VEGF-induced) angiogenesis and inhibits endochondral ossification in bone or corpora luteal development in ovary; physiologic processes that are highly dependent upon neovascularization. The growth of established human tumor xenografts (colon, lung, prostate, breast, and ovary) in athymic mice is inhibited dose-dependently by Cediranib, with chronic administration of 1.5 mg per kg per day producing statistically significant inhibition in all models. A histologic analysis of Calu-6 lung tumors treated with Cediranib reveals a reduction in microvessel density within 52 hours that becomes progressively greater with the duration of treatment. These changes are indicative of vascular regression within tumors

• 參考文獻(xiàn)：
  1. Wedge SR, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res, 2005, 65(10), 4389-4400.

• 溶解性： Soluble  in  DMSO、H2O

• 保存條件： -20℃;充氬

• 配置溶液濃度參考：
  

  	1mg	5mg	10mg
  1 mM	1.765 ml	8.825 ml	17.65 ml
  5 mM	0.353 ml	1.765 ml	3.53 ml
  10 mM	0.176 ml	0.882 ml	1.765 ml
  50 mM	0.035 ml	0.176 ml	0.353 ml

• 注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。

輸入產(chǎn)品批號(hào)：

本計(jì)算器可幫助您計(jì)算出特定溶液中溶質(zhì)的質(zhì)量、溶液濃度和體積之間的關(guān)系，公式為：

質(zhì)量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)

• pg ng μg mg g kg =
  fM pM nM μM mM M *
  nL μL mL L *